Across TCGA pan-cancer cohorts, ZNF460 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF460 data layer compared with 23 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF460 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF460 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.
PDAC, HNSC, and LUAD are the cancer types where ZNF460 mass-spec protein most reproducibly stratifies survival.